Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 3/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 3/20 | 0.33 |
| ▸ | IDH2 | P48735 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 6/20 | 0.32 |
| ▸ | KMO | O15229 | 3/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995763 | 0.81 | KDM4E (0.37) | SMARCA2SMN1; SMN2ALDH1A1 | |
| SCHEMBL17819972 | 0.74 | SORD (0.41) | SORDALDH1A1KMO | |
| SCHEMBL1256533 | 0.72 | ALDH1A1 (0.47) | SORDSMN1; SMN2ALDH1A1KMO | |
| SCHEMBL882969 | 0.72 | SORD (0.45) | SORDSMN1; SMN2ALDH1A1KMO | |
| SCHEMBL25659071 | 0.72 | SORD (0.42) | SORDALDH1A1KMO | |
| SCHEMBL17820819 | 0.72 | SORD (0.42) | SORDALDH1A1KMO | |
| SCHEMBL16421042 | 0.71 | SORD (0.44) | SORDALDH1A1KMO | |
| SCHEMBL8159378 | 0.71 | SORD (0.44) | SORDSMARCA2SMN1; SMN2ALDH1A1KMO | |
| Hydrochloric Acid SCHEMBL8170615 | 0.71 | SORD (0.44) | SORDSMN1; SMN2ALDH1A1KMO | |
| SCHEMBL25659397 | 0.70 | SORD (0.41) | SORDALDH1A1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042900-B1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | SORD 2965/4885SMARCA2 848/4885SMN1; SMN2 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.